# Pharmaceutical Retailers — company-by-company sector analysis > Pharmaceutical Retailers: High Tide Inc. owns the largest revenue base AND the fastest current growth. Sector Alpha — machine-written from the numbers. Data as of 2026-08-20. Not investment advice. ## Bottom line Pharmaceutical Retailers has underperformed S&P 500 by 41.9% over 52 weeks and 0.2% over 13 weeks. 0 of 1 covered companies beat the S&P 500 on Mansfield relative strength, while 0 of 1 beat the sector itself. High Tide Inc. leads with revenue of $671 million, based on 1 of 1 comparable companies through Jun 2026. ## Sector relative strength Pharmaceutical Retailers has underperformed S&P 500 by 41.9% over the last 52 weeks. Over 13 weeks the gap is a lead of 0.2%. 0 of 1 covered company currently beat the S&P 500 on Mansfield relative strength, so leadership inside the sector is selective. High Tide Inc. is the strongest against the sector itself at 0%. 13-week sector return versus NIFTY 500: 0.2% 52-week sector return versus NIFTY 500: -42% Stocks leading NIFTY: 0/1 Stocks leading sector: 0/1 Central tension: The central tension: current leadership is concentrated, so durability matters more than rank. Companies: 1 Combined market value: ₹216 Cr ## 4-Factor Sector Score An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment. 1. High Tide Inc. (HITI): 44/100 — Thin evidence · provisional; evidence 58% - Growth & earnings 23.8/35 | Capital efficiency 3.0/25 | Valuation 10.0/20 | Relative strength 7.5/20 - Price stage: TURNING — Ahead of the benchmark for one to four weeks, after a stretch of being behind. - Led NIFTY 500 by 5%+ over the prior 13 weeks in 0 of the last 12 weeks - Exact sum: 23.8 + 3 + 10 + 7.5 = 44.3 - Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. ## Market action High Tide Inc. has the strongest one-year price move in Pharmaceutical Retailers at -31.4%. It also leads on Mansfield relative strength against the S&P 500 at -15.7%. 0 of 1 covered company are above zero on that measure. Every line covers 314 weekly closes through 2026-08-20. ### Strongest one-year price performers 1. High Tide Inc. (HITI): -31% ### Strongest relative strength versus NIFTY 500 1. High Tide Inc. (HITI): -16% ## Revenue Scale & Growth Durability What the numbers say: High Tide Inc. is the scale leader at $671 million, High Tide Inc.'s growth is 22% from a $671 million base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale. Investor read: High Tide Inc. is the scale benchmark; High Tide Inc. is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns. This conclusion weakens if: High Tide Inc.'s growth falls below High Tide Inc.'s for two consecutive comparable reports while operating margin also compresses. Evidence: High Tide Inc. · $671 million | Not enough peers | 8/8 recent comparable periods | 1/1 companies · 20 observations Definition: Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress. ### Revenue — largest 1. High Tide Inc. (HITI): ₹671 Cr ### Revenue growth — fastest growers 1. High Tide Inc. (HITI): 22% ### 20-quarter Revenue history - HITI: Sep 2021 ₹48 Cr | Dec 2021 ₹54 Cr | Mar 2022 ₹72 Cr | Jun 2022 ₹81 Cr | Sep 2022 ₹95 Cr | Dec 2022 ₹108 Cr | Mar 2023 ₹118 Cr | Jun 2023 ₹118 Cr | Sep 2023 ₹124 Cr | Dec 2023 ₹127 Cr | Mar 2024 ₹128 Cr | Jun 2024 ₹124 Cr | Sep 2024 ₹132 Cr | Dec 2024 ₹138 Cr | Mar 2025 ₹142 Cr | Jun 2025 ₹138 Cr | Sep 2025 ₹150 Cr | Dec 2025 ₹164 Cr | Mar 2026 ₹178 Cr | Jun 2026 ₹179 Cr ### 20-quarter Revenue growth history - HITI: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 98% | Dec 2022 100% | Mar 2023 64% | Jun 2023 46% | Sep 2023 31% | Dec 2023 18% | Mar 2024 8.5% | Jun 2024 5.1% | Sep 2024 6.5% | Dec 2024 8.7% | Mar 2025 11% | Jun 2025 11% | Sep 2025 14% | Dec 2025 19% | Mar 2026 25% | Jun 2026 30% ## Operating Economics & Margin Trend What the numbers say: High Tide Inc. leads both opm at 4.1% and margin change at +2.4 percentage points. Investor read: High Tide Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it. This conclusion weakens if: The next two comparable reports reverse the current margin change signal. Evidence: High Tide Inc. · 4.1% | Not enough peers | 6/8 recent comparable periods | 1/1 companies · 20 observations Definition: Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth. ### OPM — highest 1. High Tide Inc. (HITI): 4.1% ### Margin change — fastest expanders 1. High Tide Inc. (HITI): +2.4 pp ### 20-quarter OPM history - HITI: Sep 2021 -14% | Dec 2021 -4.2% | Mar 2022 -7.3% | Jun 2022 -8.3% | Sep 2022 -4.1% | Dec 2022 -49% | Mar 2023 -2.5% | Jun 2023 -1.3% | Sep 2023 0.5% | Dec 2023 0.9% | Mar 2024 3.1% | Jun 2024 2.5% | Sep 2024 3.4% | Dec 2024 2.7% | Mar 2025 1.1% | Jun 2025 1.7% | Sep 2025 3.6% | Dec 2025 3.5% | Mar 2026 1.9% | Jun 2026 4.1% ### 20-quarter Margin change history - HITI: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 +10.1 pp | Dec 2022 −44.7 pp | Mar 2023 +4.8 pp | Jun 2023 +7.0 pp | Sep 2023 +4.6 pp | Dec 2023 +49.8 pp | Mar 2024 +5.6 pp | Jun 2024 +3.8 pp | Sep 2024 +2.9 pp | Dec 2024 +1.8 pp | Mar 2025 −2.0 pp | Jun 2025 −0.8 pp | Sep 2025 +0.2 pp | Dec 2025 +0.8 pp | Mar 2026 +0.8 pp | Jun 2026 +2.4 pp ## Profit Scale & Acceleration What the numbers say: High Tide Inc. leads net profit at $46 million net cash; the second comparison lacks enough current evidence. Investor read: High Tide Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it. This conclusion weakens if: The next two comparable reports reverse the current profit growth signal. Evidence: High Tide Inc. · $46 million net cash | Not enough peers | 0/1 recent comparable periods | 1/1 companies · 20 observations Definition: Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank. ### Net profit — largest 1. High Tide Inc. (HITI): ₹-46 Cr ### Profit growth — fastest growers ### 20-quarter Net profit history - HITI: Sep 2021 ₹-2 Cr | Dec 2021 ₹-4 Cr | Mar 2022 ₹-7 Cr | Jun 2022 ₹-8 Cr | Sep 2022 ₹-3 Cr | Dec 2022 ₹-53 Cr | Mar 2023 ₹-4 Cr | Jun 2023 ₹-2 Cr | Sep 2023 ₹-4 Cr | Dec 2023 ₹-32 Cr | Mar 2024 ₹0 Cr | Jun 2024 ₹0 Cr | Sep 2024 ₹1 Cr | Dec 2024 ₹-5 Cr | Mar 2025 ₹-3 Cr | Jun 2025 ₹-3 Cr | Sep 2025 ₹1 Cr | Dec 2025 ₹-47 Cr | Mar 2026 ₹0 Cr | Jun 2026 ₹0 Cr ### 20-quarter Profit growth history - HITI: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 — | Mar 2023 — | Jun 2023 — | Sep 2023 — | Dec 2023 — | Mar 2024 — | Jun 2024 — | Sep 2024 — | Dec 2024 — | Mar 2025 — | Jun 2025 — | Sep 2025 0.0% | Dec 2025 — | Mar 2026 — | Jun 2026 — ## Return On Capital Employed What the numbers say: High Tide Inc. leads ROCE at 3.3%. High Tide Inc. has the strongest latest improvement at +2 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability. Investor read: High Tide Inc. sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it. This conclusion weakens if: The next two comparable reports reverse the current roce change signal. Evidence: High Tide Inc. · 3.3% | Not enough peers | 6/8 recent comparable periods | 1/1 companies · 19 observations Definition: ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability. ### ROCE — highest 1. High Tide Inc. (HITI): 3.3% ### ROCE change — fastest improvers 1. High Tide Inc. (HITI): +2.0 pp ### 20-quarter ROCE history - HITI: Sep 2021 — | Dec 2021 -1.8% | Mar 2022 -2.9% | Jun 2022 -3.3% | Sep 2022 -1.7% | Dec 2022 -25% | Mar 2023 -1.3% | Jun 2023 -0.7% | Sep 2023 0.3% | Dec 2023 0.6% | Mar 2024 2.1% | Jun 2024 1.6% | Sep 2024 2.3% | Dec 2024 2.1% | Mar 2025 0.9% | Jun 2025 1.3% | Sep 2025 2.8% | Dec 2025 2.6% | Mar 2026 1.6% | Jun 2026 3.3% ### 20-quarter ROCE change history - HITI: Sep 2021 — | Dec 2021 — | Mar 2022 — | Jun 2022 — | Sep 2022 — | Dec 2022 −23.4 pp | Mar 2023 +1.6 pp | Jun 2023 +2.6 pp | Sep 2023 +2.0 pp | Dec 2023 +25.8 pp | Mar 2024 +3.4 pp | Jun 2024 +2.3 pp | Sep 2024 +2.0 pp | Dec 2024 +1.5 pp | Mar 2025 −1.2 pp | Jun 2025 −0.3 pp | Sep 2025 +0.5 pp | Dec 2025 +0.5 pp | Mar 2026 +0.7 pp | Jun 2026 +2.0 pp ## Valuation Against Growth & Quality What the numbers say: There is not enough comparable evidence to name a reliable peg leader. Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy. This conclusion weakens if: The next two comparable reports reverse the current p/e signal. Evidence: No comparable leader | Not enough peers | Not enough history | 0/1 companies · 0 observations Definition: PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing. ### PEG — lowest PEG ### P/E — lowest P/E ### 20-quarter PEG history ### 20-quarter P/E history ## What can make this comparison misleading? - A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason. - A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment. - The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed. - An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion. - Thin comparisons: Valuation have fewer than three usable current readings. ## Every company - High Tide Inc. (HITI) — market value ₹216 Cr; latest fundamentals Jun 2026 ## Methodology and freshness Fundamentals through Jun 2026; prices through 2026-08-20. Up to 20 quarters per company. Reported history is normalized to Indian rupees crore. Missing values are not interpolated. Derived metrics are calculated only when their inputs are comparable. ## Frequently asked questions ### Is the Pharmaceutical Retailers sector outperforming S&P 500? Pharmaceutical Retailers has underperformed S&P 500 by 41.9% over 52 weeks and 0.2% over 13 weeks. 0 of 1 covered companies beat the S&P 500 on Mansfield relative strength, while 0 of 1 beat the sector itself. ### Which Pharmaceutical Retailers company is largest by revenue? High Tide Inc. leads with revenue of $671 million, based on 1 of 1 comparable companies through Jun 2026. ### Which Pharmaceutical Retailers company is growing fastest? High Tide Inc. has the fastest current revenue growth at 22%, across 1 of 1 comparable companies. ### Which Pharmaceutical Retailers company has the strongest 4-Factor Sector Score? High Tide Inc. ranks first at 44.3/100 with 57.7% evidence confidence. The score prioritizes research; it is not a buy recommendation. ### How much history does this Pharmaceutical Retailers comparison include? The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated. ### How is the 4-Factor Sector Score calculated? The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral. ### Which Pharmaceutical Retailers company is the biggest? High Tide Inc. is the largest, with trailing-twelve-month revenue of $671 million. That covers 1 of 1 companies with comparable reporting through Jun 2026. ### Which Pharmaceutical Retailers company has the best profit margins? High Tide Inc. has the highest operating margin at 4.1%, from 1 of 1 comparable companies. High Tide Inc. shows the biggest recent improvement, at +2.4 percentage points. A high margin matters most when it is holding or rising, not when it is peaking. ### Which Pharmaceutical Retailers company makes the most profit? High Tide Inc. earns the most, at $46 million of trailing-twelve-month net profit, from 1 of 1 comparable companies. ### Which Pharmaceutical Retailers company earns the highest return on capital? High Tide Inc. leads on return on capital employed at 3.3%, across 1 of 1 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year. ### Is the Pharmaceutical Retailers sector beating the market? Pharmaceutical Retailers has underperformed S&P 500 by 41.9% over the last 52 weeks and 0.2% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 0 of 1 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it. ### Which Pharmaceutical Retailers stock has the strongest price momentum? High Tide Inc. has the strongest relative strength against S&P 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all. ### Which Pharmaceutical Retailers company scores highest for research priority? High Tide Inc. scores 44.3 out of 100 with 57.7% evidence confidence, from 23.8 points on growth and earnings, 3 on capital efficiency, 10 on valuation and 7.5 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research. ### How many Pharmaceutical Retailers companies does this comparison cover, and over what period? It compares 1 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data. ### What is the total market cap of the Pharmaceutical Retailers sector? The 1 Pharmaceutical Retailers companies on this page carry $216 million of combined market value. High Tide Inc. is the largest at $216 million, about 100% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-20. ### How is the Pharmaceutical Retailers sector performing? 0 of the 1 covered Pharmaceutical Retailers companies are beating S&P 500 on Mansfield relative strength. The sector itself is 41.9% behind S&P 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-20. ### How many Pharmaceutical Retailers stocks are listed in the US? This comparison covers 1 listed Pharmaceutical Retailers companies in the US, each above the size floor the site applies. The full ranked list is on this page, with reported fundamentals through Jun 2026. Membership is the full industry list — nothing is dropped for having thin data. ### Why are some values on this page blank? A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad. ### Is this investment advice? No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.